- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT01005680
A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer
perjantai 18. lokakuuta 2013 päivittänyt: Eli Lilly and Company
A Randomized Phase 3 Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin as First-Line Treatment in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer.
The purpose of this study is to compare the efficacy and safety of two different chemotherapy types in the first line treatment of advanced Non-Small Cell Lung Cancer (NSCLC).
Tutkimuksen yleiskatsaus
Tila
Valmis
Interventio / Hoito
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
256
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
-
Beijing, Kiina, 100730
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Changchun, Kiina, 130012
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Dalian, Kiina, 116023
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Guang Zhou, Kiina, 510080
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Nanjing, Kiina, 210002
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Nanning, Kiina, 530000
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Shanghai, Kiina, 200433
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Sichuan, Kiina, 610041
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Ei
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion Criteria:
- Present with histologically proven or cytological diagnosis of non-squamous non-small cell lung cancer (NSCLC) Stage IIIB or IV.
- Participants must agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug.
- Female participants must not be pregnant.
- No prior systemic chemotherapy for lung cancer.
- At least one unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors.
- Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.
- Adequate organ function.
- Prior radiation therapy allowed to <25% of the bone marrow.
- Signed informed consent document on file.
- Estimated life expectancy of greater than or equal to 12 weeks.
- Participant compliance and geographic proximity that allow adequate follow up.
Exclusion Criteria:
- Peripheral neuropathy of great than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1.
- Inability to comply with protocol or study procedures.
- A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the participant's ability to complete the study.
- A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV.
- Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
- Documented brain metastases unless the participant has completed successful local therapy for central nervous system metastases and has not taken corticosteroids for at least 4 weeks before enrollment.
- Presence of clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.
- Significant weight loss (that is, greater than or equal to 10%) over the previous 6 weeks before study entry.
- Concurrent administration of any other anti-tumor therapy.
- Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents, such as piroxicam).
- Inability or unwillingness to take folic acid or vitamin B12 supplementation.
- Inability to take corticosteroids.
- Pregnant or breast-feeding.
- Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Pemetrexed plus Cisplatin
|
500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
Muut nimet:
75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
|
Active Comparator: Gemcitabine plus Cisplatin
|
75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Overall Survival (OS)
Aikaikkuna: Randomization to date of death from any cause up to 35.8 months post-randomization
|
OS was defined as the duration from date of randomization to date of death from any cause.
Participants who were alive were censored at the date of last contact.
|
Randomization to date of death from any cause up to 35.8 months post-randomization
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Progression Free Survival (PFS)
Aikaikkuna: Randomization to first date of Progressive Disease (PD) or death from any cause up to 33.0 months post-randomization
|
PFS was defined as the date of randomization to date of first observation of clinical or objective progressive disease (PD) or death due to any cause.
PD assessed using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of one or more new lesions.
Participants who were not known to have died or had PD were censored at the date of last contact.
|
Randomization to first date of Progressive Disease (PD) or death from any cause up to 33.0 months post-randomization
|
Time to Progressive Disease (TtPD)
Aikaikkuna: Randomization to first date of PD up to 23.7 months post-randomization
|
TtPD defined as the time from study randomization to the first date of progressive disease (PD).
PD assessed using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions.
Participants who were not known to have PD or who died without PD were censored at the date of last of last tumor assessment.
|
Randomization to first date of PD up to 23.7 months post-randomization
|
Duration of Response (DoR)
Aikaikkuna: Date of first response to the date of (PD) or death from any cause up to 22.9 months post-randomization
|
DoR was defined as the time from first objective status assessment of complete response (CR) or partial response (PR) to the first time progressive disease (PD) or death as a result of any cause.
Response using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria.
CR was defined as the disappearance of all target lesions.
PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.
Participants who are not known to have died or to have PD were censored at the date of last contact.
PD assessed using RECIST v1.0 and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions
|
Date of first response to the date of (PD) or death from any cause up to 22.9 months post-randomization
|
Time to Treatment Failure (TtTF)
Aikaikkuna: Randomization until date of discontinuation of study treatment due to adverse events, PD, or death from any cause up to 6.3 months post-randomization
|
TtTF was defined as date of randomization until the date of discontinuation of study treatment due to adverse event, progressive disease (PD), or death from any cause.
PD assessed using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions.
Participants who discontinued study treatment for any other reason were censored at the date of discontinuation of study treatment.
Participants still on study drug at data-inclusion cut-off date were censored at the cut-off date.
|
Randomization until date of discontinuation of study treatment due to adverse events, PD, or death from any cause up to 6.3 months post-randomization
|
Tumor Response Rate
Aikaikkuna: Randomization until date of objective PD or death from any cause up to 35.8 months post-randomization
|
Tumor response rate was the percentage of participants with confirmed best tumor response of complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumor (RECIST v1.0) criteria.
Complete Response (CR) was defined as the disappearance of all target lesions; Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions.
Progressive disease (PD) assessed using RECIST v1.0 criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions.
|
Randomization until date of objective PD or death from any cause up to 35.8 months post-randomization
|
Risk/Benefit Ratio
Aikaikkuna: Randomization to date of death from any cause up to 35.8 months post-randomization
|
Risk/benefit ratio was calculated as the percentage of participants who experienced a study-drug related toxicity of Common Terminology Criteria for Adverse Events (CTCAE v3.0) Cancer Therapy Evaluation Program (CTEP) Grade 3 or higher, divided by the Kaplan-Meier estimated percentage of participants surviving one year.
|
Randomization to date of death from any cause up to 35.8 months post-randomization
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Disease Control Rate (DCR)
Aikaikkuna: Randomization to date of objective PD or death from any cause up to 35.8 months post-randomization
|
DCR was the percentage of participants with Complete Response (CR), Partial Response (PR), and Stable Disease (SD).
Response determined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0) criteria.
CR was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in sum of longest diameter of target lesions; progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter ever recorded since study treatment started, or the appearance of 1 or more new lesions; SD was defined as small changes that did not meet the above criteria.
|
Randomization to date of objective PD or death from any cause up to 35.8 months post-randomization
|
Survival Without Toxicity (SWT)
Aikaikkuna: Randomization to date of toxicity or date of death up to 34.6 months post-randomization
|
SWT was defined as the time from randomization to a study-drug related toxicity.
Toxicity was defined as Common Terminology Criteria for Adverse Events (CTCAE v3.0) Grade 3 or 4 or death.
Participants who do not have a CTCAE Grade 3 or higher toxicity and are alive will be censored at the date of last contact.
|
Randomization to date of toxicity or date of death up to 34.6 months post-randomization
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Sunnuntai 1. marraskuuta 2009
Ensisijainen valmistuminen (Todellinen)
Torstai 1. marraskuuta 2012
Opintojen valmistuminen (Todellinen)
Torstai 1. marraskuuta 2012
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Torstai 29. lokakuuta 2009
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Torstai 29. lokakuuta 2009
Ensimmäinen Lähetetty (Arvio)
Sunnuntai 1. marraskuuta 2009
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Perjantai 13. joulukuuta 2013
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Perjantai 18. lokakuuta 2013
Viimeksi vahvistettu
Tiistai 1. lokakuuta 2013
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Hengityselinten sairaudet
- Neoplasmat
- Keuhkosairaudet
- Neoplasmat sivustoittain
- Hengitysteiden kasvaimet
- Rintakehän kasvaimet
- Syöpä, bronkogeeninen
- Keuhkoputkien kasvaimet
- Keuhkojen kasvaimet
- Karsinooma, ei-pienisoluinen keuhko
- Huumeiden fysiologiset vaikutukset
- Farmakologisen vaikutuksen molekyylimekanismit
- Infektiota estävät aineet
- Viruksenvastaiset aineet
- Nukleiinihapposynteesin estäjät
- Entsyymin estäjät
- Antimetaboliitit, antineoplastiset
- Antimetaboliitit
- Antineoplastiset aineet
- Immunosuppressiiviset aineet
- Immunologiset tekijät
- Foolihappoantagonistit
- Gemsitabiini
- Sisplatiini
- Pemetreksedi
Muut tutkimustunnusnumerot
- 12878
- H3E-CR-JMIL (Muu tunniste: Eli Lilly and Company)
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Ei-pienisoluinen keuhkosyöpä
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.Aktiivinen, ei rekrytointiMetastaattinen keuhkojen ei-pienisolusyöpä | Tulenkestävä keuhkojen ei-pienisolusyöpä | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | Stage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8Yhdysvallat
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RekrytointiStage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | Keuhkojen ei-pienisolukarsinooma | Vaiheen III keuhkosyöpä AJCC v8 | IV vaiheen keuhkosyöpä AJCC v8 | Vaiheen II keuhkosyöpä AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Vaiheen IIB keuhkosyöpä AJCC v8 | Vaiheen IIIA keuhkosyöpä AJCC v8 | Vaiheen IIIB... ja muut ehdotYhdysvallat
-
Eben RosenthalRekrytointiStage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | IV vaiheen keuhkosyöpä AJCC v8 | Keuhkokarsinooma | Metastaattinen pahanlaatuinen kasvain keuhkoissaYhdysvallat
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)LopetettuPienisoluinen keuhkosyöpä | Stage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | IV vaiheen keuhkosyöpä AJCC v8Yhdysvallat
-
Emory UniversityNational Cancer Institute (NCI)RekrytointiStage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | Keuhkojen ei-pienisolukarsinooma | IV vaiheen keuhkosyöpä AJCC v8Yhdysvallat
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; California Institute... ja muut yhteistyökumppanitAktiivinen, ei rekrytointiStage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | Keuhkojen ei-pienisolukarsinooma | IV vaiheen keuhkosyöpä AJCC v8Yhdysvallat
-
Ohio State University Comprehensive Cancer CenterRekrytointiStage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | IV vaiheen keuhkosyöpä AJCC v8 | Keuhkojen ei-squamous ei-pienisolusyöpä | Vaiheen IIIB keuhkosyöpä AJCC v8Yhdysvallat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiivinen, ei rekrytointiStage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | Vaiheen III keuhkosyöpä AJCC v8 | IV vaiheen keuhkosyöpä AJCC v8 | Vaiheen II keuhkosyöpä AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Vaiheen IIB keuhkosyöpä AJCC v8 | Vaiheen IIIA keuhkosyöpä AJCC v8 | Vaiheen IIIB keuhkosyöpä AJCC v8 | I vaiheen... ja muut ehdotYhdysvallat
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RekrytointiMetastaattinen keuhkojen ei-pienisolusyöpä | Stage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | Vaiheen III keuhkosyöpä AJCC v8 | IV vaiheen keuhkosyöpä AJCC v8 | Vaiheen II keuhkosyöpä AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Vaiheen IIB keuhkosyöpä AJCC v8 | Vaiheen IIIA keuhkosyöpä AJCC v8 | Vaiheen... ja muut ehdotYhdysvallat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)PeruutettuStage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8 | Keuhkojen ei-pienisolukarsinooma | Vaiheen III keuhkosyöpä AJCC v8 | IV vaiheen keuhkosyöpä AJCC v8 | Vaiheen II keuhkosyöpä AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Vaiheen IIB keuhkosyöpä AJCC v8 | Vaiheen IIIA keuhkosyöpä AJCC v8 | Vaiheen IIIB... ja muut ehdot
Kliiniset tutkimukset Pemetrexed
-
IO BiotechMerck Sharp & Dohme LLCValmisNSCLCYhdistynyt kuningaskunta, Saksa, Alankomaat, Espanja
-
Innate PharmaRekrytointiEi-pienisoluinen keuhkosyöpäRanska, Yhdysvallat, Kreikka, Unkari, Puola
-
Pharmacyclics LLC.LopetettuEi-pienisoluinen keuhkosyöpäYhdysvallat
-
Avistone Biotechnology Co., Ltd.Ei vielä rekrytointia
-
GlaxoSmithKlineEi vielä rekrytointiaKeuhkosyöpä, ei-pienisoluinenYhdistynyt kuningaskunta
-
Bio-Thera SolutionsEi vielä rekrytointiaKarsinooma, ei-pienisoluinen keuhko
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Rekrytointi
-
Julia K. Rotow, MDInivataAktiivinen, ei rekrytointiMetastaattinen ei-pienisoluinen keuhkosyöpä | NSCLC vaihe IVYhdysvallat
-
Innovent Biologics (Suzhou) Co. Ltd.ValmisSyöpä, kiinteä kasvainKiina